ALK and acute myeloid leukemia: According to a study, gilteritinib, a TKI approved for the treatment of acute myeloid leukemia (AML) that has relapsed or become resistant to treatment, suppresses both single ALK-TKI-resistant mutants and compound mutants with the mutation I1171N both in vitro and in vivo [121].